Commercial Times / China Times 2026.1.30
https://www.chinatimes.com/newspapers/20231120000253-260210?
NanoRay Biotech’s innovative cancer precision therapy, Auger Molecular Therapy (AMT), has been honored with the 2025 National Innovation Award, highlighting the company’s R&D excellence in integrating radiological medicine with precision treatment. This therapy combines targeted radiation with specific drugs, featuring low systemic toxicity and high selectivity for cancer cells. Only under targeted radiation exposure does it precisely deliver high-energy DNA damage to cancer cells, enhancing therapeutic efficacy while minimizing side effects.
NanoRay Biotech stated that the key to AMT lies in its independently developed spectrally tunable X-ray source technology. The patented penetrative X-ray tube, designed in-house, is compact and mobile, enabling integration with portable treatment platforms. This design not only suits large medical centers but also facilitates deployment in regional hospitals and rural clinics, improving accessibility to advanced healthcare.
Currently, AMT has entered Phase I clinical trials, with preliminary results indicating high safety and promising therapeutic potential beyond conventional treatments, paving the way for a new direction in precision cancer medicine.
NanoRay Biotech’s innovative cancer precision therapy, Auger Molecular Therapy (AMT), has won the National Innovation Award.
Provided by NanoRay Biotech